



**WHO Consultation on MERS CoV R&D:
Development of a Global MERS CoV R&D Roadmap – Salle A**

10-11 December 2015,

LIST OF PARTICIPANTS

PARTICIPANTS:

Mohammed Al-Hajri, Director, Emergency Preparedness and Response, Supreme Council of Health, **Qatar**

Hail Mater Alabdely, Director-General, Health Facilities Infection Control, Ministry of Health, Riyadh, **Saudi Arabia**

Abdullah Mufareh Assiri, Assistant Deputy Minister Preventive Health, Ministry of Health, Riyadh, **Saudi Arabia**

Abdulaziz Bin Saeed, Deputy Minister of Health, Ministry of Health, Riyadh, **Saudi Arabia**

Simon Cauchemez, Imperial College London, **United Kingdom of Great Britain & Northern Ireland**

Christoph Conrad, Scientist, Major Policy Issues, International Relations, **Paul-Ehrlich-Institut**, Langen, **Germany**

Christian Drosten, Institute of Virology, University of Bonn, **Germany**

Moulay Ahmed El Idrissi Hamzi, Food and Agriculture Organization of the United Nations, Rome, **Italy**

Luis Enjuanes, Coronavirus Laboratory Head, Centro Nacional de Biotecnología, Madrid, **Spain**

Matt Freiman, University of Maryland School of Medicine, Baltimore, **United States of America**

Andrea Gambotto, Assistant Professor, University of Pittsburgh, School of Medicine, **United States of America**

Barney S. Graham, Deputy Director, Chief, Viral Pathogenesis Laboratory and Translational Science Core, Vaccine Research Center, NIAID, NIH, Bethesda, **United States of America**

Bart Haagmans, Erasmus Medical Centre, Rotterdam, **Netherlands**

Ruth Harvey, Scientist, Department of Virology, National Institute for Biological Standards and Control, Health Protection Agency, Potters Bar, **United Kingdom of Great Britain & Northern Ireland**

Frederick Hayden, Professor of Clinical Virology, Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, **United States of America**

Ahmad Salah Hersi, Chairman, Scientific Advisory Board, Ministry Of Health, Riyadh, **Saudi Arabia**

David Kaslow, Vice President, Product Development, PATH, Seattle, **United States of America**

Youngmee Jee, Director, Center for Immunology and Pathology, Centre for Disease Control and Prevention, Seoul, **Republic of Korea**

Kent Tseng Chien-Te, Associate Professor, Department of Microbiology and Immunology Director, SARS and MERS P3 laboratories Member, Center of, Galveston, Texas, **United States of America**

Jerome H. Kim, Director General, International Vaccine Institute, Seoul, **Republic of Korea**

Marion Koopmans, Erasmus Medical Centre, Rotterdam, **Netherlands**

John Lowenthal, Research Director, Emerging Infectious Diseases, CSIRO Animal Health Laboratory, Victoria, **Australia**

Wayne Marasco, Harvard Medical School, Boston, MA, **United States of America**

Kayvon Modjarrad, US Military HIV Research Program, Walter Reed Army Institute of Research, Rockville, **United States of America**

Michael Muhleback, Veterinary Medicine, Paul Ehrlich Institute, Langen, **Germany**

Myoung-don Oh, Department of Internal Medicine, National University College of Medicine, Seoul, **Republic of Korea**

Grounalan Pavade, World Organization for Animal Health (OIE), Paris, **France**

Eric Pelfrene, Anti-Infectives and Vaccines, European Medicines Agency, London, **United Kingdom of Great Britain & Northern Ireland**

Gerd Sutter, Professor and Chair for Virology, Institute for Infectious Diseases and Zoonoses Ludwig-Maximilians-Universität, München, **Germany**

Wenjie Tan, China CDC, **People's Republic of China**

Maria Van Kerkhove, Center for Global health, Institut Pasteur, Paris

Linqi Zhang, Department of Basic Medical Sciences, Tsinghua University, **People's Republic of China**

OBSERVERS:

Rick Bright, Director - Influenza Division, Biomedical Advanced Research & Development Authority (BARDA), **US Department of Health and Human Services (HHS)**, Washington, **United States of America**

Tomas Cihlar, Senior Director of Biology, Foster City, California, **United States of America**

Davide Corti, CSO, Humabs BioMed SA, Bellinzona, **Switzerland**

James Cummings, Director, Emerging Infectious Diseases, Novavax, Maryland, **United States of America**

Mary Kosinski, BARDA Chief of Staff, U.S. Department of Health and Human Services, Washington, **United States of America**

Joel Maslow, Chief Medical Officer, GeneOne Life Science Inc, Seoul, **Republic of Korea**

Young Park, President & CEO, GeneOne Life Science, Inc., Seoul, **Republic of Korea**

Nadia Passini, Project Manager, Humabs BioMed SA, Bellinzona, **Switzerland**

Patrick Rambaud, President and CEO, Organic Vaccines, Dublin, **Ireland**

Robin Robinson, Director, Biomedical Advanced Research and Development Authority, Deputy Assistant Secretary for Preparedness, Washington, **United States of America**

Uwe Staerz, Chief Scientist, Geffex Inc., Aurora, **United States of America**

Erik Stemmy, Human Coronavirus Research Program Officer, DMID/NIAID, Rockville, Maryland, **United States of America**

Eddie Sullivan, President/CEO, SAB Biotherapeutics, INC., Sioux Falls, **United States of America**

Anton Tikhonov, Organic Vaccines, Dublin, **Ireland**

Birgit Van Tongelen, DG Research & Innovation, European Commission, Brussels, **Belgium**

Sebastian Wanless, Chief Medical Officer, Brighton Biotech, Princeton, New Jersey, **United States of America**

In-Kyu Yoon, International Vaccine Institute, Seoul, **Republic of Korea**

WHO/HQ SECRETARIAT

Marie-Paule Kieny, Assistant Director-General, Health Systems & Innovation Cluster

Sylvie Briand, Director, Pandemic and Epidemic Diseases Department

Vasee Moorthy, WHO Blueprint Team, & Team Leader, Vaccine Development, Department of Immunization, Vaccines & Biologicals

Peter Ben Embarek, MERS-CoV Taskforce manager, Department of Food Safety and Zoonoses

Peter Beyer, Senior Advisor, Department of Essential Medicines

Bernadette Murgue, WHO Blueprint Facilitator, Health Systems & Innovation Cluster

Cathy Roth, Advisor, Office of the Assistant Director-General, Health Systems and Innovation Cluster

Tony Stewart, Global Outbreak and Response Network

David Wood, Coordinator, Norms and Standards, Department of Essential Medicines